http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#Head http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8 http://www.nanopub.org/nschema#hasAssertion http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#assertion http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8 http://www.nanopub.org/nschema#hasProvenance http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#provenance http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8 http://www.nanopub.org/nschema#hasPublicationInfo http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#pubinfo http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#assertion http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_1 http://purl.obolibrary.org/obo/BFO_0000051 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_2 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_1 http://purl.obolibrary.org/obo/BFO_0000051 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_3 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_1 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://amigo.geneontology.org/amigo/term/GO:0043234 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_2 http://purl.obolibrary.org/obo/RO_0002204 http://www.informatics.jax.org/marker/MGI:104740 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_3 http://purl.obolibrary.org/obo/RO_0002204 http://www.informatics.jax.org/marker/MGI:98216 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_3 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_4 http://purl.obolibrary.org/obo/BFO_0000066 http://purl.obolibrary.org/obo/UBERON_0001969 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_4 http://purl.obolibrary.org/obo/BFO_0000066 http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=10090 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_4 http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_1 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_4 http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate http://www.selventa.com/vocabulary/decreases http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_4 http://www.w3.org/1999/02/22-rdf-syntax-ns#subject http://resource.belframework.org/belframework/20131211/namespace/selventa-legacy-chemicals/fibrate http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_4 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#assertion http://www.w3.org/2000/01/rdf-schema#label a(SCHEM:fibrate) -| complex(p(MGI:Ppara),p(MGI:Rxrg)) http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#provenance http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/description Approximately 61,000 statements. http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/rights Copyright (c) 2011-2012, Selventa. All rights reserved. http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/title BEL Framework Large Corpus Document http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/pav/authoredBy http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_6 http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/pav/version 20131211 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_5 http://www.w3.org/ns/prov#value The hypolipidemic fibric acid drugs are peroxisome proliferator-activated receptor a (PPAR alpha) ligands. PPAR alpha activated by fibric acids form heterodimers with the 9-cis retinoic acid receptor (RXR). The PPAR/RXR heterodimers bind to peroxisome proliferator response elements (PPRE), which are located in numerous gene promoters and increase the level of the expression of mRNAs encoded by PPAR alpha target genes. Fibric acids decrease triglyceride plasma levels through increases in the expression of genes involved in fatty acid-beta oxidation. Furthermore, they decrease triglycerides by increasing lipoprotein lipase gene expression and by decreasing apolipoprotein C-III gene expression. Fibric acids increase high-density lipoprotein (HDL) cholesterol partly by increasing apolipoprotein A-I and apolipoprotein A-II gene expression. Fibric acids also reduce vascular wall inflammation and the expression of genes involved in different vascular functions (ie, vasomotricity, thrombosis). Fibric acids are used to treat primary hypertriglyceridemia and mixed hyperlipidemia. Some fibric acid molecules are active in essential hypercholesterolemia. Clinical evidence shows that fibric acids reduce coronary atherosclerosis progression in dyslipidemic patients (eg, bezafibrate, gemfibrozil) and in type 2 diabetic patients (fenofibrate). Gemfibrozil decreases coronary morbidity and mortality in patients with low HDL cholesterol, normal triglycerides,and normal low-density lipoprotein (LDL) cholesterol plasma levels. Further clinical studies are necessary to investigate if fibric acids decrease cardiovascular mortality in type 2 diabetes and in primary prevention of hypertriglyceridemia and hypolipidemia. http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_5 http://www.w3.org/ns/prov#wasQuotedFrom http://www.ncbi.nlm.nih.gov/pubmed/11123853 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_6 http://www.w3.org/2000/01/rdf-schema#label Selventa http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#assertion http://www.w3.org/ns/prov#hadPrimarySource http://www.ncbi.nlm.nih.gov/pubmed/11123853 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#assertion http://www.w3.org/ns/prov#wasDerivedFrom http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#assertion http://www.w3.org/ns/prov#wasDerivedFrom http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#_5 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8#pubinfo http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8 http://purl.org/dc/terms/created 2014-07-03T14:31:38.904+02:00 http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8 http://purl.org/pav/createdBy http://orcid.org/0000-0001-6818-334X http://www.tkuhn.ch/bel2nanopub/RAAmlPNJ8J6a_OoVTh4YUsMQQP0YJlIXWJTJ0pGmRh3s8 http://purl.org/pav/createdBy http://orcid.org/0000-0002-1267-0234